Our editorial simply asked for consistency in the standards to which innovator manufacturers and biosimilar manufacturers are held with respect to international nonproprietary names (INNs). Is it truly scientific to state that comparability assessments are always completely different from similarity assessments and that the kind of intra-manufacturer changes in the processing and production of a brand biologic under a comparability assessment would never result in changes to the product that would warrant a change in INN?